KDR and hepatocellular carcinoma: Sorafenib, the first drug approved for advanced HCC, is a tyrosine kinase inhibitor that targets VEGFR2 and Raf kinase.4 While Sorafenib treatment showed survival benefits in Phase III clinical studies,5, 6 many HCC patients still failed to respond, or developed resistance after being treated for several months.7